ARTICLES|ONLINE FIRST Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial E Wesley Ely, Athimalaipet V Ramanan, Cynthia E Kartman, et al Lancet Respir Med Published:February 03, 2022 DOI:https://doi.org/10.1016/S2213-2600(22)00006-6 Summary Background ...

ORIGINAL ARTICLEFREE PREVIEW SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection Paul Feuerstadt, Thomas J. Louie, Bret Lashner, et al N Engl J Med 2022; 386:220-229DOI: 10.1056/NEJMoa2106516 Abstract BACKGROUND Current therapies for recurrent Clostridioides difficile infection do not address the disrupted microbiome, which supports C. difficile spore germination into toxin-producing bacteria...

ARTICLES| VOLUME 22, ISSUE 2, P196-208, FEBRUARY 01, 2022 Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial ShengLi Xia, YunTao Zhang, YanXia Wang, et al Lancet Infect Dis 2022; 22: 196-208 Summary Background Although SARS-CoV-2 infection often causes milder symptoms in children and adolescents, young people might still play a k...

ORIGINAL ARTICLEFREE PREVIEW Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants Laura L. Hammitt, Ron Dagan, Yuan Yuan, et al N Engl J Med 2022; 386:837-846DOI: 10.1056/NEJMoa2110275 Abstract BACKGROUND Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life. The efficacy and s...

ORIGINAL ARTICLE Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines Nick Andrews, Elise Tessier, Julia Stowe, et al N Engl J Med January 12, 2022DOI: 10.1056/NEJMoa2115481 Abstract BACKGROUND Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since December 2020 in the United Kingdom. Real-world data have shown the vaccines ...

ARTICLES| VOLUME 22, ISSUE 2, P209-221, FEBRUARY 01, 2022 Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, et al Lancet Infect Dis 2022; 22: 209-221 Summary Background The antiviral efficacy of remdesivir against SARS-CoV-2 is still controversia...

ORIGINAL ARTICLEFREE PREVIEW High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality P.J. Devereaux, Andre Lamy, Matthew T.V. Chan, et al N Engl J Med 2022; 386:827-836DOI: 10.1056/NEJMoa2000803 Abstract BACKGROUND Consensus recommendations regarding the threshold levels of cardiac troponin elevations for the definition of perioperative myocardial infarction and clinically important periprocedural myocardial injury in patients undergo...

ORIGINAL ARTICLEFREE PREVIEW Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults Simon Finfer, Sharon Micallef, Naomi Hammond, et al N Engl J Med January 18, 2022DOI: 10.1056/NEJMoa2114464 Abstract BACKGROUND Whether the use of balanced multielectrolyte solution (BMES) in preference to 0.9% sodium chloride solution (saline) in critically ill patients reduces the risk of acute kidney injury or death is uncertain. METH...

ARTICLES| VOLUME 22, ISSUE 2, P183-195, FEBRUARY 01, 2022 Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study Anika Singanayagam, Seran Hakki, Jake Dunning, et al Lancet Infect Dis 2022; 22: 183-195 Summary Background The SARS-CoV-2 delta (B.1.617.2) variant is highly transmissible and spreading globally, i...

Research Letter December 3, 2021 Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals Brian Grunau, David M. Goldfarb, Michael Asamoah-Boaheng, et al JAMA. 2022;327(3):279-281. doi:10.1001/jama.2021.21921 Standard dosing intervals for BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines are 21 and 28 days, respectively.1 Data suggest improved effectiveness of ChAdOx1 adenoviral2 and other nonreplicating va...